Foghorn Therapeutics(FHTX) - 2023 Q2 - Quarterly Report

Table of Contents For the quarterly period ended June 30, 2023 Commission File Number: 001-39634 ______________________ 02139 (Zip Code) Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x As of July 31, 2023, the registrant had 41,862,174 shares of common stock, $0.0001 par value per share, outstanding. i • the initiation, timing, progress and results of our research and development programs, preclinical and clinical studies; 1 | --- | ...